|
Daily Medical Update
Migraine & Tension Headaches (CGRP inhibitors)
Tuesday, February 17, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Headache (2026) - Practice Guideline
Key Findings
- AHS ED evidence assessment found better acute symptom improvement with migraine-directed non-opioid regimens (e.g., dopamine-antagonist antiemetics/NSAID-based strategies) versus nonspecific escalation approaches.
- Across assessed parenteral regimens, efficacy signals favored targeted migraine-directed agents over nonspecific analgesic escalation in emergency care pathways.
📋 Practice Implication: In urgent/ED migraine presentations, align acute treatment with AHS evidence-based non-opioid protocols and ensure PCP follow-up for preventive optimization if attacks recur.
|
Pharmacotherapy (2026) - Systematic Review
Key Findings
- AI/ML response-prediction performance was inconsistent across datasets, with weaker accuracy on external validation and no reproducible superiority versus standard clinical decision pathways.
- Current evidence is insufficient for routine bedside treatment selection; prospective validation is still needed before broad clinical deployment.
📋 Practice Implication: Do not use AI tools alone to pick migraine drugs yet; use them only as adjuncts while continuing standard guideline-based medication selection and monitoring.
|
Headache (2026) - Meta-Analysis
Key Findings
- Real-world meta-analysis showed clinically meaningful early improvement with galcanezumab, including ~6.9 fewer monthly migraine days at 1 month (95% CI -7.88 to -5.99).
- Headache burden measures (including MHD and HIT-6) also improved substantially, supporting effectiveness outside tightly controlled trial settings.
📋 Practice Implication: For patients with frequent migraines despite first-line preventives, consider earlier CGRP mAb escalation (e.g., galcanezumab) and reassess response within 4-8 weeks.
|
Headache (2025) - Meta-Analysis
Key Findings
- In chronic migraine with medication overuse, erenumab reduced monthly migraine days versus control (MD -1.88; 95% CI -2.68 to -1.07).
- Benefits included reduced acute-medication-use days, supporting its role in overuse-prone patients when combined with medication-overuse counseling.
📋 Practice Implication: For chronic migraine plus medication overuse, consider erenumab while simultaneously implementing a structured acute-medication de-escalation plan.
|
Expert review of pharmacoeconomics & outcomes research (2026) - Systematic Review
Key Findings
- Economic modeling found lower adverse-event-related costs with rimegepant versus lasmiditan, with estimated savings of about €613 per treated patient over ~6 months.
- Lower modeled tolerability burden suggests rimegepant may improve persistence when adverse effects drive discontinuation in acute therapy.
📋 Practice Implication: When acute migraine options are clinically similar, favor better-tolerated choices such as rimegepant to reduce side-effect burden and downstream care costs.
|
|
Across recent high-evidence studies, CGRP-targeted therapies and related migraine strategies continue to show clinically meaningful reductions in migraine burden for selected patients. For PCP workflows, the practical shift is earlier evidence-based selection of preventive and acute options with attention to contraindications, adverse effects, and insurance access. Guideline-level and synthesis evidence supports individualized escalation when first-line therapies are insufficient.
|
|